To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06581406
Title A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (RP2-202)
Acronym RP2-202
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Replimune Inc.
Indications
Therapies
Age Groups: child | adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
HonorHealth Research Insisute RECRUITING Scottsdale Arizona 85258 United States Details
UC San Diego Moores Cancer Center RECRUITING La Jolla California 92037 United States Details
Stanford Cancer Institute RECRUITING Palo Alto California 94304 United States Details
Emory Winship Cancer Institute RECRUITING Atlanta Georgia 30322 United States Details
University of Iowa RECRUITING Iowa City Iowa 52242 United States Details
Duke University Medical Center RECRUITING Durham North Carolina 27710 United States Details
Thomas Jefferson University RECRUITING Philadelphia Pennsylvania 19107 United States Details
UPMC Hillman Cancer Center RECRUITING Pittsburgh Pennsylvania 15232 United States Details
The University Of Texas Md Anderson Cancer Center RECRUITING Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field